Vitruvian Partners LLP Buys Shares of 5,043,356 MaxCyte, Inc. $MXCT

Vitruvian Partners LLP purchased a new position in shares of MaxCyte, Inc. (NASDAQ:MXCT - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 5,043,356 shares of the company's stock, valued at approximately $6,203,328. MaxCyte comprises approximately 0.0% of Vitruvian Partners LLP's portfolio, making the stock its 6th biggest holding. Vitruvian Partners LLP owned approximately 4.71% of MaxCyte as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also modified their holdings of the company. Prudential Financial Inc. purchased a new position in shares of MaxCyte during the 2nd quarter worth approximately $26,000. State of Wyoming purchased a new stake in shares of MaxCyte during the second quarter valued at $38,000. Jain Global LLC acquired a new stake in shares of MaxCyte in the fourth quarter worth about $45,000. BNP Paribas Financial Markets boosted its position in MaxCyte by 39.5% in the third quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company's stock valued at $57,000 after buying an additional 10,263 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in MaxCyte in the fourth quarter worth $67,000. Institutional investors own 68.81% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on MXCT. Weiss Ratings upgraded shares of MaxCyte from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday. Wall Street Zen upgraded MaxCyte from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, BTIG Research reaffirmed a "neutral" rating on shares of MaxCyte in a research note on Monday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $5.00.

MaxCyte Trading Down 4.3%

Shares of NASDAQ:MXCT traded down $0.06 during trading on Friday, reaching $1.23. 331,513 shares of the company traded hands, compared to its average volume of 1,084,682. The business's fifty day moving average is $1.23 and its 200-day moving average is $1.01. The firm has a market capitalization of $126.43 million, a price-to-earnings ratio of -3.71 and a beta of 1.48. MaxCyte, Inc. has a 52-week low of $0.64 and a 52-week high of $1.86.

MaxCyte (NASDAQ:MXCT - Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.01. MaxCyte had a negative net margin of 114.77% and a negative return on equity of 18.92%. The business had revenue of $6.50 million for the quarter, compared to analyst estimates of $6.51 million. On average, sell-side analysts predict that MaxCyte, Inc. will post -0.25 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.